-
Component patterns and survival outcomes in patients with mixed malignant ovarian germ cell tumors: a retrospective cohort study Clin. Oncol. (IF 3.4) Pub Date : 2024-03-16 Sijian Li, Rundong Zhang, Xinyue Zhang, Tianyu Zhang, Dongyan Cao, Yang Xiang, Jiaxin Yang
To evaluate the component patterns and risk stratification in patients with mixed malignant ovarian germ cell tumors (mMOGCT). A retrospective study of 70 mMOGCT patients treated in our hospital between 2000 and 2022 was conducted. The recurrence-free survival (RFS), disease-specific survival (DSS), and risk stratification system based on scoring the identified prognostic factors were assessed. Yolk
-
Federated learning survival model and potential radiotherapy decision support impact assessment for non-small cell lung cancer using real-world data Clin. Oncol. (IF 3.4) Pub Date : 2024-03-16 Matthew Field, Shalini Vinod, Geoff P. Delaney, Noel Aherne, Michael Bailey, Martin Carolan, Andre Dekker, Stuart Greenham, Eric Hau, Joerg Lehmann, Joanna Ludbrook, Andrew Miller, Angela Rezo, Jothybasu Selvaraj, Jonathan Sykes, David Thwaites, Lois Holloway
The objective of this study was to develop a two-year overall survival model for inoperable stage I-III non-small cell lung cancer (NSCLC) patients using routine radiation oncology data over a federated (distributed) learning network and evaluate the potential of decision support for curative versus palliative radiotherapy. A federated infrastructure of data extraction, de-identification, standardization
-
Shared Decision Making in Oncology Care: Translating to clinical practice Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 Chloe Holden, Alison Keen, Amélie Harle, Ian S. Boon
-
North-South Divide: Chemo-Immunotherapy Combination in Head and Neck Squamous Cell Cancer (HNSCC) Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 Ian S. Boon, Cheng S. Boon, Kenneth Oguejiofor, Shanmugasundaram Ramkumar
-
How long does contouring really take? Results of the Royal College of Radiologists contouring surveys Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 Dr Emily Montague, Dr Tom Roques, Dr Katie Spencer, Dr Alexander Burnett, Joanna Lourenco, Dr Nicky Thorp
The success and safety of modern radiotherapy relies on accurate contouring. Understanding the time taken to complete radiotherapy contours is critical to informing workforce planning and, in the context of a workforce shortfall, advocating for investment in technology and multi-professional skills mix. We aimed to quantify the time taken to delineate target volumes for radical radiotherapy. The Royal
-
A Randomised Phase II Trial to Evaluate the Feasibility of Radiotherapy Dose Escalation, Facilitated by Intensity Modulated Arc Radiotherapy Techniques, in High-Risk Neuroblastoma Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 Jennifer E. Gains, Amit Patel, Yen-Ch’ing Chang, Henry C. Mandeville, Gregory Smyth, Christopher Stacey, James Talbot, Keith Wheatley, Mark N. Gaze
AND PURPOSE: For high-risk neuroblastoma, planning target volume coverage is often compromised to respect adjacent kidney tolerance. This trial investigated whether intensity modulated arc radiotherapy techniques (IMAT) could facilitate dose escalation better than conventional techniques. Children with high-risk abdominal neuroblastoma referred for radiotherapy to the primary tumour site and involved
-
Radiomics for clinical decision support in radiation oncology Clin. Oncol. (IF 3.4) Pub Date : 2024-03-15 Luca Russo, Charles-Davies Diepriye, Silvia Bottazzi, Evis Sala, Luca Boldrini
Radiomics is a promising tool for the development of quantitative biomarkers to support clinical decision-making. It has been shown to improve the prediction of response to treatment and outcome in different settings, particularly in the field of radiation oncology by optimising the dose delivery solutions and reducing the rate of radiation-induced side effects, leading to a fully personalised approach
-
High-dose-rate brachytherapy monotherapy in patients with localized prostate cancer: Dose modelling and optimization using computer algorithms Clin. Oncol. (IF 3.4) Pub Date : 2024-03-14 Kata Dabic-Stankovic, Katarina Rajkovic, Jovan Stankovic, Goran Marosevic, Goran Kolarevic, Bojan Pavicar
Interstitial High–Dose-Rate brachytherapy (HDR-BT) is an effective therapy modality for patients with localized prostate carcinoma. The objectives of the study was to optimize the therapy regime variables using two models: Response surface methodology (RSM) and Artificial Neural Network (ANN). 31 studies with 5651 patients were included (2078 patients presented as with low-risk, 3077 patients with
-
VOLUMETRIC RESPONSE AND SURVIVAL OF PATIENTS WITH BULKY IDH-MUTATED GRADE 3 GLIOMA MANAGED WITH FET-FDG GUIDED INTEGRATED BOOST IMRT. Clin. Oncol. (IF 3.4) Pub Date : 2024-03-13 D. Mills, P. Horsley, V. Venkatasha, M. Back
Despite relatively favourable outcomes associated with IDH-mutant Grade 3 gliomas, many patients present with diffuse non-enhancing disease involving multiple brain regions, prompting concern over both durable disease control and the morbidity associated with large volume radiation therapy. This study audits volumetric response, survival and functional outcomes in this ‘large volume’ subgroup who undergo
-
National survey of current follow-up protocols for patients treated for endometrial cancer in the UK Clin. Oncol. (IF 3.4) Pub Date : 2024-03-13 Hersha Patel, Karl Drinkwater, Alexandra Stewart
The aim of this study was to establish a baseline of national practice for follow up after treatment for endometrial cancer in the UK. An online cross-sectional survey was developed and distributed through the Royal College of Radiologists via an email link to the audit leads of radiotherapy centres in the UK. The survey was conducted from November 2021 to 5 January 2022. The main themes assessed in
-
OncoFlash – Research Updates in a Flash! (April 2024 Edition) Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 M. Denholm, C. Crockett
-
Audit of Outcomes from Bone Biopsies in Patients with Suspected or Progressive Metastatic Breast Cancer Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 A. Young, D. Roi, S. Cleator
-
Interstitial Lung Disease Associated with Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer: a Real-world Experience Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 A. Shaheen, H. Hayhurst, O. Omokhodion, A. Ayyad
-
Real-world Data Collection of Toxicity Data from Patients on Everolimus and Exemestane in a Large UK Tertiary Oncology Centre Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 S. Raby, F. Coe, V. Misra
-
The Prognostic Value of Low HER2 Expression on Treatment Outcomes in Metastatic Hormone Receptor-positive Breast Cancer Patients Treated with CDK4/6 Inhibitors and Endocrine Therapy Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 R. Muhammad, S. Mumtaz, N. Goyal, A. Konstantis
-
Comparison of Target Volume Coverage and Organs at Risk in Contoured Regional Nodes versus a Field-based Approach in Adjuvant Breast Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 C. Guo, C. Kane, A. Anderson, M. Lovegrove, S. Needleman
-
NICE Technology Appraisals in Breast Oncology and the Impact on Cancer Treatment Unit Activity at the Sussex Cancer Network – 10-year Update Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 K. Eremeishvili, R. Simcock, P. Savage
-
Incidence and Management of Transtuzumab Emtansine- and Transtuzumab Deruxetecan-related Pneumonitis in Breast Cancer Patients within Leicester Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 S. Bhagani, O. Akala
-
Assessing Agreement to the Use of Hormone Replacement Therapy for Breast Cancer Patients Experiencing Menopausal Symptoms Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 A. Ali, A. Branson, P. Bradley
-
Gut Microbiota Predict Efficacy of Neoadjuvant Systemic Therapy in Patients with Early Breast Cancer Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 K. Ross, B. Nichols, R. Papadopoulou, M. Macleod, J. Fraser, S. Barrett, K. Teo, E. Mallon, A. Ammar, J. Edwards, J. Evans, K. Gerasimidis, I. Macpherson
-
Audit of Hypersensitivity Reactions (HSRs) of Patients with Breast Cancer being Treated with Nab-paclitaxel after Severe HSR to Prior Taxane Chemotherapy; is it Safe? Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 M. Jaschke, X. Ren, C. Michie
-
Estimated Absolute Risks from Typical UK Radiotherapy for Early Breast Cancer During 2015–2023 Clin. Oncol. (IF 3.4) Pub Date : 2024-03-07 F. Holt, A. Ivanova, N. Roberts, Z. Wang, D. Dodwell, C. Taylor
-
Interventions for Managing Late Gastrointestinal Symptoms Following Pelvic Radiotherapy: a Systematic Review and Meta-analysis Clin. Oncol. (IF 3.4) Pub Date : 2024-02-19 H. Berntsson, A. Thien, D. Hind, L. Stewart, M. Mahzabin, W.S. Tung, M. Bradburn, M. Kurien
Pelvic radiotherapy can induce gastrointestinal injury and symptoms, which can affect quality of life. We assessed interventions for managing these symptoms. A review of randomised controlled trials published between January 1990 and June 2023 from databases including MEDLINE, EMBASE, CENTRAL, CINAHL, , ISRCTN and grey literature sources was conducted. Meta-analyses were carried out using the DerSimonian
-
Oral Cavity Cancers: Ethnic Differences in Radiotherapy Outcomes in a Majority South Asian Leicester Community Clin. Oncol. (IF 3.4) Pub Date : 2024-02-15 N. Patil, N. Ma, M. Mair, J. Nazareth, A. Sim, C. Reynolds, N. Freeman, M. Chauhan, L. Howells, D. Peel, S. Ahmad, T. Sridhar, H.S. Walter
Squamous cell carcinoma oral cavity cancers (SCCOCCs) have a higher reported incidence in South Asian countries. We sought to compare presenting stage and outcome by ethnicity in patients with SCCOCC treated with radical radiotherapy in a single centre in the UK. All patients with SCCOCC treated with radical radiotherapy at an oncology department in Leicester (UK) between 2011 and 2017 were identified
-
Pharyngeal Constrictor Muscle Sparing in Head and Neck Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-02-15 K. Oguejiofor, C.S. Boon, S. Ramkumar, I.S. Boon
-
OncoFlash–Research Updates in a Flash! (Mar 2024) Clin. Oncol. (IF 3.4) Pub Date : 2024-02-14 A. Chowdhury, C. Lorimer
-
-
-
NLRP3 Inflammasome: A Potential Therapeutic Target in Head and Neck Cancers Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 S. Sekaran, S. Warrier, V. Selvaraj, D. Ganapathy, P. Ramasamy
-
The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 A. Thapa, A. Cowell, A. Peters, D.J. Noble, A. James, C. Lamb, D. Grose, S. Vohra, S. Schipani, K. Mactier, J. Mackenzie, D. Srinivasan, K. Laws, R. Moleron, P. Niblock, F.-Y. Soh, C. Paterson, C. Wilson
The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence, who approved monotherapy alone in England and Wales. The aim of this study was to provide real-world performance data
-
National Institute for Health and Care Excellence and Royal College of Radiologists' Fractionation Guideline for Metastatic Spinal Cord Compression Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 J.S. Lim, C.S. Boon, K. Oguejiofor, S. Ramkumar, I.S. Boon
-
The Increasing Role of Genomics Testing in Thyroid Cancers Clin. Oncol. (IF 3.4) Pub Date : 2024-02-12 I.S. Boon
-
Contralateral Nodal Relapse in Well-lateralised Oral Cavity Cancers Treated Uniformly with Ipsilateral Surgery and Adjuvant Radiotherapy With or Without Concurrent Chemotherapy: a Retrospective Study Clin. Oncol. (IF 3.4) Pub Date : 2024-02-10 M. Swain, A. Budrukkar, V. Murthy, P. Pai, A. Kanoja, S. Ghosh-Laskar, A. Deshmukh, G. Pantvaidya, S. Kannan, V.M. Patil, V. Naronha, K. Prabhash, S. Sinha, A. Kumar, T. Gupta, J. Agarwal
To evaluate the incidence and pattern of contralateral nodal relapse (CLNR), contralateral nodal relapse-free survival (CLNRFS) and risk factors predicting CLNR in well-lateralised oral cavity cancers (OCC) treated with unilateral surgery and adjuvant ipsilateral radiotherapy with or without concurrent chemotherapy. Consecutive patients of well-lateralised OCC treated between 2012 and 2017 were included
-
Predicting Survival with Brain Metastases in the Stereotactic Radiosurgery Era: are Existing Prognostic Scores Still Relevant? Or Can we do Better? Clin. Oncol. (IF 3.4) Pub Date : 2024-02-09 M.W. Fittall, M. Brewer, J. de Boisanger, L. Kviat, A. Babiker, H. Taylor, F. Saran, J. Konadu, F. Solda, A. Creak, L.C. Welsh, N. Rosenfelder
Predicting survival is essential to tailoring treatment for patients diagnosed with brain metastases. We have evaluated the performance of widely used, validated prognostic scoring systems (Graded Prognostic Assessment and diagnosis-specific Graded Prognostic Assessment) in over 1000 ‘real-world’ patients treated with stereotactic radiosurgery to the brain, selected according to National Health Service
-
Prehabilitation for Patients with Cancer Undergoing Radiation Therapy: a Scoping Review Clin. Oncol. (IF 3.4) Pub Date : 2024-02-08 E. Harris, L. Marignol
Prehabilitation is a process of identifying and assessing factors that could compromise the physical and psychological health of patients undergoing cancer treatment and implementing an intervention to combat such concerns. The use of prehabilitation in cancer surgery has yielded positive outcomes in rectal, lung and abdominal cancers. Prehabilitation strategies have potential to improve the management
-
Quality of Decision Making in Radiation Oncology Clin. Oncol. (IF 3.4) Pub Date : 2024-02-06 S.K. Vinod, R. Merie, S. Harden
High-quality decision making in radiation oncology requires the careful consideration of multiple factors. In addition to the evidence-based indications for curative or palliative radiotherapy, this article explores how, in routine clinical practice, we also need to account for many other factors when making high-quality decisions. Foremost are patient-related factors, including preference, and the
-
The National Radiotherapy Trials Quality Assurance Group – Driving up Quality in Clinical Research and Clinical Care Clin. Oncol. (IF 3.4) Pub Date : 2024-02-02 E. Miles, J. Wadsley, P. Diez, R. Patel, S. Gwynne
Abstract not available
-
Quality of Radiotherapy Workforce Training within the USA Clin. Oncol. (IF 3.4) Pub Date : 2024-02-02 R. Mulherkar, D.C. Ling, R. Tendulkar, M.R. Kamrava, S. Beriwal
The training, competency requirements and scope of practice of professionals within a radiation oncology department vary across countries. The purpose of this review is to shed light on the current status of radiotherapy training in the USA by discussing current benchmarks for medical residency, physics residency, radiation therapy and dosimetry training programmes. Although there are notable strengths
-
Clinicopathological Profile and Survival Outcomes in Patients with Localised Extremity Synovial Sarcomas Clin. Oncol. (IF 3.4) Pub Date : 2024-02-01 J. Sharma, S.V.S. Deo, S. Kumar, A.W. Barwad, S. Rastogi, D.N. Sharma, G. Singh, S. Bhoriwal, A. Mishra, R. K, J. Saikia, A. Mandal, B. Bansal, M. Gaur
Synovial sarcoma is a rare but aggressive variant of soft-tissue sarcoma. Literature is sparse and reported mostly from the West. We analysed the clinical profiles and prognostic factors of extremity synovial sarcoma patients in order to study their clinical journey. This was a retrospective analysis. All patients with extremity synovial sarcoma treated between 1992 and 2020 were included. Patients
-
Efficacy and Safety of Preoperative Transcatheter Rectal Arterial Chemoembolisation in Patients with Locally Advanced Rectal Cancer: Results from a Prospective, Phase II PCAR Trial Clin. Oncol. (IF 3.4) Pub Date : 2024-01-29 Weina Yang, Chengyuan Qian, Jiamin Luo, Chuan Chen, Yan Feng, Nan Dai, Xuemei Li, Xiao He, Yuxin Yang, Mengxia Li, Chunxue Li, Dong Wang
Aims The PCAR study aimed to assess the efficacy and safety of preoperative transcatheter rectal arterial chemoembolisation (TRACE) in patients with locally advanced rectal cancer (LARC). Materials and methods This was a single-centre, prospective, phase II trial conducted in China. Eligible patients were adults aged 18 years and older with histologically confirmed stage II or III rectal carcinoma
-
Big Data and Colorectal Cancer: The Revolution will be Personalised Clin. Oncol. (IF 3.4) Pub Date : 2024-01-23 Christopher J.M. Williams, Jenny F. Seligmann
Abstract not available
-
Trends and Variation in the Use of Radiotherapy in Non-metastatic Rectal Cancer: a 14-year Nationwide Overview from the Netherlands Clin. Oncol. (IF 3.4) Pub Date : 2024-01-20 A.-S.E. Verrijssen, J. Evers, M. van der Sangen, S. Siesling, M.J. Aarts, H. Struikmans, M.C.W.M. Bloemers, J. Burger, V. Lemmens, P. Braam, M. Elferink, M. Berbee
Aims This study describes nationwide primary radiotherapy utilisation trends for non-metastasised rectal cancer in the Netherlands between 2008 and 2021. In 2014, both colorectal cancer screening and a new guideline specifying prognostic risk groups for neoadjuvant treatment were implemented. Materials and methods Patients with non-metastasised rectal cancer in 2008–2021 (n = 37 510) were selected
-
Evaluation of Delivered Doses in Proton Beam Therapy for Prostate Cancer Using Positron Emission Tomography/Computed Tomography Imaging Clin. Oncol. (IF 3.4) Pub Date : 2024-01-19 S. Shiraishi, M. Yamanaka, T. Murai, K. Tokuuye
Aims Proton beams deposit energy along their paths and stop abruptly without penetrating the opposite side, making it difficult to detect their actual paths. However, confirming the path may lead to evaluating the actual doses to organs at risk in proton therapy for prostate cancer. As proton beams produce positron emitters through nuclear fragmentation reactions, theoretically, proton beam paths can
-
An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent Clin. Oncol. (IF 3.4) Pub Date : 2024-01-20 S. Rajagopal, X. Yao, W. Abadir, T.D. Baetz, A.M. Easson, G. Knight, E. McWhirter, C. Nessim, C.F. Rosen, A. Sun, F.C. Wright, T.M. Petrella
To make recommendations on managing the surveillance of patients with stage I, II, III or resectable IV melanoma who are clinically free of disease following treatment with curative intent. This guideline was developed by Ontario Health's (Cancer Care Ontario's) Program in Evidence-Based Care and the Melanoma Disease Site Group (including seven medical oncologists, four surgical oncologists, three
-
Improved Dosimetry with Daily Online Adaptive Radiotherapy for Cervical Cancer: Waltzing the Pear Clin. Oncol. (IF 3.4) Pub Date : 2024-01-17 A. Yen, Xinran Zhong, Mu-Han Lin, C. Nwachukwu, K. Albuquerque, B. Hrycushko
Aims Standard of care radiotherapy for locally advanced cervical cancer includes large margins to ensure the uterocervix remains within the treatment fields over the course of treatment. Daily online cone-beam adaptive radiotherapy corrects for interfractional changes by adjusting the plan to match the target position during each treatment session, thus allowing for significantly reduced clinical target
-
Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial Clin. Oncol. (IF 3.4) Pub Date : 2024-01-17 E.M. Cruz-Lim, B. Mou, W. Jiang, M. Liu, A. Bergman, D. Schellenberg, A. Alexander, T. Berrang, A. Bang, N. Chng, Q. Matthews, H. Carolan, F. Hsu, S. Miller, S. Atrchian, E. Chan, C. Ho, I. Mohamed, A. Lin, V. Huang, S. Baker
Aims Most patients experience stable quality of life (QoL) after stereotactic ablative radiotherapy (SABR) treatment for oligometastases. However, a subset of patients experience clinically relevant declines in QoL on post-treatment follow-up. This study aimed to identify risk factors for QoL decline. Materials and methods The [AQ1]SABR-5 trial was a population-based single-arm phase II study of SABR
-
A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-01-16 A. Lerner, A.J.X. Lee, H. Yan, J. Van Griethuysen, A.D. Bartlett, M. Veli, Y. Jiang, M. Luong, N. Naban, C. Kane, J. Conibear, D. Papadatos-Pastos, T. Ahmad, D. Chao, G. Anand, U.S. Asghar
We present 7 years of clinical experience with single-agent pembrolizumab immune checkpoint inhibitor immunotherapy in non-small cell lung cancers (NSCLC) from four UK cancer centres. This multi-institutional retrospective cohort study included 226 metastatic NSCLC patients. Outcomes were number and severity of immune-related adverse events (irAEs), median progression-free survival (mPFS) and median
-
Decline in Cancer Diagnoses during the ‘Zero COVID’ Policy in Hong Kong: Indirect Spillover Impact of the COVID-19 Pandemic Clin. Oncol. (IF 3.4) Pub Date : 2024-01-16 H.M. Youn, Y. Zhang, A. Liu, C.S. Ng, J. Liang, G.K.K. Lau, S.F. Lee, J. Lok, C.L.K. Lam, E.Y.F. Wan, J. Quan
Aims Despite a largely successful ‘zero COVID’ policy in 2020, the COVID-19 pandemic disrupted routine cancer services in the city of Hong Kong. The aims of this study were to examine the trends in cancer incidence before and during the COVID-19 pandemic and estimate missed cancer diagnoses. Materials and methods We used population-based data from the Hong Kong Cancer Registry 1983–2020 to examine
-
Pharyngeal Constrictor Dose–Volume Histogram Metrics and Patient-Reported Dysphagia in Head and Neck Radiotherapy Clin. Oncol. (IF 3.4) Pub Date : 2024-01-11 O. Paetkau, S. Weppler, J. Kwok, H.C. Quon, C. Gomes da Rocha, W. Smith, E. Tchistiakova, C. Kirkby
Aims Head and neck radiotherapy long-term survival continues to improve and the management of long-term side-effects is moving to the forefront of patient care. Dysphagia is associated with dose to the pharyngeal constrictors and can be measured using patient-reported outcomes to evaluate its effect on quality of life. The aim of the present study was to relate pharyngeal constrictor dose–volume parameters
-
Commentary on the New National Institute for Health and Care Excellence Guideline for Metastatic Spinal Cord Compression Clin. Oncol. (IF 3.4) Pub Date : 2024-01-11 S. Growcott, E. Renninson, L. Rayner, J. McKeon, G. Ayre, C. Comins, A. Challapalli, W. Owadally, M. Beasley, L. Hawley, S. Hilman, T. Strawson-Smith, A. Bahl
Abstract not available
-
Will Immune Checkpoint Inhibitors Allow the Non-operative Management of Mismatch Repair-deficient Colorectal Cancer to Become a Standard of Care? Clin. Oncol. (IF 3.4) Pub Date : 2024-01-14 H. Sinclair, T. Ranji, D.C. Gilbert
Abstract not available
-
Intraoperative Imaging Techniques in Oncology Clin. Oncol. (IF 3.4) Pub Date : 2024-01-11 S.S. Vulasala, P. Sutphin, P. Shyn, S. Kalva
Imaging-based procedures have become well integrated into the diagnosis and management of oncological patients and play a significant role in reducing morbidity and mortality rates. Here we describe the established and upcoming surgical oncological imaging techniques and their impact on cancer management.
-
-
OncoFlash–Research Updates in a Flash! (Feb 2024) Clin. Oncol. (IF 3.4) Pub Date : 2024-01-08 S. Parikh, K. Thippu Jayaprakash
Abstract not available
-
Drug Appraisal Recommendations in Urological Oncology and Impact on Cancer Treatment Unit Visits at Sussex Cancer Network – 10-year Update Clin. Oncol. (IF 3.4) Pub Date : 2023-12-20 K. Eremeishvili, P. Savage
Abstract not available
-
OncoFlash – Research updates in a Flash! January 24 edition Clin. Oncol. (IF 3.4) Pub Date : 2023-12-20 D. Shor, R. Simoes
Abstract not available
-
Enhancement and Size-based Response Criteria for Evaluating Tyrosine Kinase Inhibitor Dosing Strategy in Metastatic Renal Cancer: Prospective Imaging Study from the UK STAR Trial Clin. Oncol. (IF 3.4) Pub Date : 2023-12-20 T. Manickavasagar, C. Kelly-Morland, T.M. Wah, P. Nathan, J. Brown, V. Goh
Abstract not available
-
Bone Health Management in Advanced Prostate Cancer: a Survey of UK Genitourinary Healthcare Professionals (GU HCPs) Clin. Oncol. (IF 3.4) Pub Date : 2023-12-20 C. Navarro-Rodriguez, D. Manoharan, R. McMenemin, R. Pearson, A. Birtle, H. Payne, X.Y. Jiang
Abstract not available
-
STAMPEDE2 Trial: a Survey on National Variations in Access to Novel Imaging in Metastatic Prostate Cancer and Implications for Trial Conduct Clin. Oncol. (IF 3.4) Pub Date : 2023-12-20 H. Abdel-Aty, L. O’Shea, C. Amos, L.C. Brown, E. Grist, G. Attard
Abstract not available
-
Is the Addition of Pelvic Nodal Irradiation Beneficial in Postoperative Salvage Radiotherapy for Prostate Cancer? Clin. Oncol. (IF 3.4) Pub Date : 2023-12-20 A. Batty, S.O. Bokhari, J. Doherty, H. Wong, I. Syndikus, R. Walshaw
Abstract not available